跳至主要内容
临床试验/CTRI/2022/06/043370
CTRI/2022/06/043370已完成不适用

A randomized, double-blind, placebo controlled, clinical study to measure the effect of natural phytochemical formulation on muscle fatigue, endurance energy supply, recovery and neuro muscular activation in delayed onset muscle soreness (DOMS), and related inflammation and stress in healthy untrained subjects.

AureaBiolabs Private Limited2 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2022年4月7日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
110
试验地点
2
主要终点
1) Change in muscle fatigue

研究概览

简要总结

This clinicalstudy will be conducted to measure the effect of natural phytochemicalformulation on the muscle fatigue, endurance energy supply, recovery and neuromuscular activation in delayed muscle soreness (DOMS),and related inflammation and stress in healthy subjects. Total 110 subjectswill be enrolled in the study.

All the subjectswill be screened based on inclusion and exclusion criteria. Subjects whofulfilled the requirement will enrolled in the study. All the subjects will befollowed up for day 4, 15, 30 and 60.The vitals and physical examination willbe recorded during screening and also during all the visits in entire study.During randomization, performance of eccentric exercise, assessment of subjectivepainrating (NPRS), assessment of muscle fatigue with fatigue index will bemeasured. On respective visit, change in muscle fatigue, change in enduranceenergy supply and recovery, change in neuro muscular activation, change instress and anti-inflammatory biomarkers, change in BP and pulse, change in CBCand blood lipids and measuring subjective pain score.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
19.00 Year(s) 至 50.00 Year(s)(—)
性别
All

入选标准

  • Subject has provided written, signed and dated informed consent to participate in the study.
  • Subject is willing and able to comply with the protocol, 3) Male or female subjects between 19-50 years of age (both inclusive).
  • Subjects should be untrained as defined by, less active that is regular exercise for less than 4 h per week.
  • Subject is in good health as determined by a health history and as per Investigator discretion.
  • Subject is untrained in resistance/power exercise.

排除标准

  • Subject is participating in another clinical trial or has received an investigational product within thirty days prior to enrollment.
  • Subject has a history of alcohol or other drug abuse in the past year.
  • Subject has a significant history or current presence of treated or untreated bleeding disorder, diabetes mellitus, high blood pressure (BP) [systolic BP> 140 and/or diastolic BP> 90], thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease.
  • Subject currently suffers from a sleep disorder and/or has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s), which in the opinion of the investigator, might put the subject at risk and/or confound the results of the study.
  • Subject has a known allergy or sensitivity to any ingredient in the test product.
  • Subject has any medical condition or uses any medication, nutritional product, dietary supplement or program, which in the opinion of the investigator, might interfere with the conduct of the study or place the subject at risk.
  • Subject has used creatine within 9 weeks prior to screening.
  • Subject has a history of orthopedic injury or surgery within the last year.
  • Subject has any physical condition considered a contraindication to the type of exercise performed in the study.
  • Subject has had an abnormal resting ECG.
  • Investigator is uncertain about subject’s capability or willingsness to comply with the protocol requirments.

结局指标

主要结局

1) Change in muscle fatigue

时间窗: 30 days.

4) Change in stress and anti-inflammatory biomarkers

时间窗: 30 days.

2) Change in endurance energy supply and recovery

时间窗: 30 days.

3) Change in neuro muscular activation

时间窗: 30 days.

6) Change in CBC and blood lipids

时间窗: 30 days.

5) Change in BP and pulse

时间窗: 30 days.

7) Subjective pain score: Subjective pain rating will be inspected utilizing a

时间窗: 30 days.

numericalpain intensity scale. The visual assessment score (VAS) scale ranged from 0 (no pain at all) to 10 (extremely intense pain)

时间窗: 30 days.

次要结局

  • Type and incidence of adverse events.(30 days.)

研究者

发起方
AureaBiolabs Private Limited
申办方类型
Other [Nutraceutical Company]

研究点 (2)

Loading locations...

相似试验